The collaboration marks the first time that Sensyne and Phesi have entered a joint commercial collaboration with a pharmaceutical client since they entered into a strategic alliance in January 2021. The development work to be undertaken involves the analysis of anonymised and de-identified real world patient data available to Sensyne with Phesi’s clinical trial data in order to optimise the design of a clinical trial programme for the client.
No financial terms have been disclosed for this collaboration.
About Sensyne – Phesi Strategic Alliance
Under the terms of the strategic alliance agreement, Sensyne and Phesi agreed to collaborate on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools combining clinical trial data with real world patient data. Phesi’s clients include many of the world’s leading pharmaceutical and biotechnology companies.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“I’m delighted to announce our first pharmaceutical collaboration with Phesi which demonstrates the benefits of combining our expertise in clinical trials, real world patient data and AI-driven analytics.”
Dr. Gen Li, Founder and President of Phesi Inc., said:
“I am looking forward to seeing our first collaboration with Sensyne come to fruition. Integrated predictive analytics is set to play a vital role in optimizing clinical development, and our work together will enable more life sciences organizations to become data-driven. Unlocking the power of data through this approach is crucial to meeting unmet medical needs around the world.”